Another phase 2/3 clinical trial (NCT04655976) is evaluating its combination application with docetaxel and dostarlimab in NSCLC patients with prior progressive disease to anti-PD-1/PD-L1 drugs [96]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.